Part VII: Interventions

South African Medical Journal

Volumn 101, Issue 8, 2011, Pages 587-595

  Visser, A ^a   Moore, D P ^a   Whitelaw, A ^a   Lowman, W ^a   Kantor, G ^a   Hoosen, A ^a   Madhi, S ^a   Brink, A ^a   van Den Bergh, D D ^a   Devenish, L ^a   Moodley, P ^a   Apalata, T ^a   Duse, A G ^a   Gelband, H ^a  

^a NONE

Author keywords

Antibiotic resistance; Infection control; Prescribing practices; Standard treatment guidelines; Surveillance; Vaccination

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG COST; DRUG DISTRIBUTION; DRUG MANUFACTURE; DRUG SURVEILLANCE PROGRAM; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; INTERVENTION STUDY; PRACTICE GUIDELINE; PRESCRIPTION; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIA; TETANUS; VACCINATION;

ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES; DRUG RESISTANCE, BACTERIAL; HUMANS; INFECTION CONTROL; NATIONAL HEALTH PROGRAMS; PREVENTIVE HEALTH SERVICES; SOUTH AFRICA;

EID: 79960979727     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Baker L. The face of South Africa's Expanded Programme on Immunization (EPI) schedule. SA Pharmaceutical Journal 2010; January/February:18-20.
2. Hadler SC, Dietz V, Okwo-Bele JM, Cutts FT. Immunization in developing countries. In: Plotkin SA, Orenstein WA, Oft PA, eds. Vaccines. 5th ed. Philadelphia: Saunders Elsevier, 2008: 1541-1571.
3. Centers for Disease Control and Prevention. Decrease in prevalence of vaccine preventable diseases in the USA through 1998. MMWR Morb Mortal Wkly Rep 1999;48:243-248
4. UNICEF. www.unicef.org/immunization/index_coverage.html (accessed 23 April 2011).
5. GAVI. http://www.gavialliance.org/performance/country_results/index.php (accessed 23 April 2011).
6. Ngcobo N, Cameron N. Introducing new vaccines into the childhood immunization programme in South Africa. South Afr J Epidemiol Infect 2010;25(4):3-4.
7. Department of Health. www.savic.ac.za/backend/docs/Vaccinators%20Manual%20-%202005%20 part1.pdf 8-11 (accessed 18 July 2011).
8. Hussey G, Wisonge C. EPI in South Africa - challenges and prospects. Presentation at the Proceedings of Vaccinology Congress, Hermanus, 2010.
9. Greenblatt B. Emergency vaccine supply. Presentation at the Proceedings of Vaccinology Congress, Hermanus, 2009
10. Vergeer W. Regulation of human vaccines in South Africa. Presentation at the Proceedings of Vaccinology Congress, Hermanus, 2010.
11. World Health Organization. http://www.who.int/countries/zaf/en (accessed 26 April 2011).
12. Biovac. www.biovac.co.za (accessed 23 April 2011).
13. Health Systems Trust. http://www.hst.org.za/health-indicators (accessed 23 April 2011).
14. Benson F. 2010 mass vaccination campaigns - rationale and planning. Presentation at Proceedings of Vaccinology Congress, Hermanus, 2010.
15. Heever JVD. Mass immunization: lessons learnt: technical issues. Presentation at Proceedings of Vaccinology Congress, Hermanus, 2010.
16. Ward J, Cherry J, Chang S, et al. Efcacy of an accelular pertussis vaccine among adolescents and adults. New Engl J Med 2005;353(15):1555-1563.
17. Rie AV, Hethcote H. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004;22(23):3154-3165.
18. Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa. GERMS-SA Annual Report 2010. http://nicd.ac.za/?page=germs-sa&id=97 (accessed 18 July 2011).
19. Karstaedt A, Khoosal M, Crewe-Brown H. Pneumococcal bacteremia during a decade in children in Soweto. Pediatr Infect Dis J 2000;19(5):454-457.
20. Lynch J, Zhanel G. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance and impact of vaccines. Curr Opin Pulm Med 2010;16(3):217-225.
21. Gladstone R, Jefres J, Faust S, Clarke S. Continued control of pneumococcal disease in the UK - the impact of vaccination. J Med Microbiol 2011;Jan(60):1-8.
22. Klugman K, Madhi S, Huebner R, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349(14):1341-1348.
23. Madhi S, Kuwanda L, Cutland C, Klugman K. Te impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005;40(10):1511-1518.
24. Blencowe H, Lawn J, Vandelaer J, Roper M. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol 2010;39:102-109.
25. Zar H, Madhi S. Childhood pneumonia - progress and challenges. S Afr Med J 2006;96(9):890-900.
26. Hussey G, Hitchcock H, Schaaf G. Epidemiology of invasive Haemophilus infuenzae infections in Cape Town, South Africa. Ann Trop Paediatr 1994;14:97-103.
27. City of Johannesburg. Soweto Integrated Spatial Framework; 2008. http://www.joburg-archive. co.za/2008/sdf/soweto/soweto_statusquo_context.pdf (accessed 27 April 2011).
28. Ramchander P. Towards the responsible management of the socio-cultural impact of township tourism. University of Pretoria; 2004. http://upetd.up.ac.za/thesis/available/etd-08262004-130507/ unrestricted/02chapter2.pdf (accessed 27 April 2011).
29. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349(14):1341-1348.
30. World Bank. 2011. http://www.data.worldbank.org/indicator/SH.DYN.MORT?page=3 (accessed 27 April 2011).
31. Sanders D, Bradshaw D, Ngongo N. The status of child health in South Africa. In: Kibel M, ed. South African Child Gauge 2009/2010. Cape Town: University of Cape Town, 2010:29-40. http://www.ci.org.za/depts/ci/ pubs/pdf/general/gauge2009-10/south_african_child_gauge_09-10.pdf (accessed 27 April 2011).
32. Gow JA. Te adequacy of policy responses to the treatment needs of South Africans living with HIV (1999-2008): a case study. J Int AIDS Soc 2009;12:37.
33. Zwi KJ, Pettifor JM, Soderlund N. Paediatric hospital admissions at a South African urban regional hospital: the impact of HIV, 1992-1997. Ann Trop Paediatr 1999;19(2):135-142.
34. Zwi K, Pettifor J, Soderlund N, Meyers T. HIV infection and in-hospital mortality at an academic hospital in South Africa. Arch Dis Child 2000;83(3):227-230.
35. Meyers TM, Pettifor JM, Gray GE, Crewe-Brown H, Galpin JS. Pediatric admissions with human immunodefciency virus infection at a regional hospital in Soweto, South Africa. J Trop Pediatr 2000;46(4):224-230.
36. Schneider H, Kellerman R, Oyedele S. HIV Impact Surveillance System. Johannesburg: University of the Witwatersrand School of Public Health and Gauteng Department of Health, 2005. http://www. docstoc.com/docs/24446107/HIV-IMPACT-SURVEILLANCE-SYSTEM-SUMMARY-REPORT (accessed 27 April 2011).
37. Dramowski A. A Profle of HIV-related Paediatric Admissions at Chris Hani Baragwanath Hospital, Johannesburg, South Africa. Johannesburg: University of the Witwatersrand, 2008. http://wiredspace. wits.ac.za/bitstream/handle/10539/7545/dramowski_fnal%20report.pdf;jsessionid=4D83714C16B65 C42A8D9E6E921C13165?sequence=1 (accessed 27 April 2011).
38. USAID. Global Report. In: Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the Global AIDS Epidemic 2010: UNAIDS; 2010. http://www.unaids.org/globalreport/ documents/20101123_GlobalReport_full_en.pdf (accessed 27 April 2011).
39. Nunes MC, von Gottberg A, de Gouveia L, et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011;25(4):453-462.
40. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodefciency virus type 1-infected children. Clin Infect Dis 2000;31(1):170-176.
41. Madhi SA, Madhi A, Petersen K, Khoosal M, Klugman K P. Impact of human immunodefciency virus type 1 infection on the epidemiology and outcome of bacterial meningitis in South African children. Int J Infect Dis 2001;5(3):119-125.
42. Cutts FT, Zaman SM, Enwere G, et al. Efcacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005;365:1139-1146.
43. Anonymous. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007;82(12):93-104.
44. Progress in Introduction of Pneumococcal Conjugate Vaccine - Worldwide, 2000-2008. JAMA 2009;301(1):31-32.
45. Levine OS, Knoll MD, Jones A, Walker DG, Risko N, Gilani Z. Global status of Haemophilus infuenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. Curr Opin Infect Dis 2010;23(3):236-241.
46. Madhi SA, Klugman K P. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004;10(8):811-813.
47. Madhi SA, Ludewick H, Kuwanda L, et al. Pneumococcal coinfection with human metapneumovirus. J Infect Dis 2006;193(9):1236-1243.
48. Klugman K P, Madhi SA. Pneumococcal vaccines and fu preparedness. Science 2007;316(5821):49-50.
49. Madhi SA, Klugman K P. World Health Organization defnition of 'radiologically-confrmed pneumonia' may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine 2007;25(13):2413-2419.
50. Klugman K P, Madhi SA, Albrich WC. Novel approaches to the identifcation of Streptococcus pneumoniae as the cause of community-acquired pneumonia. Clin Infect Dis 2008;47 Suppl 3:S202-S206.
51. Madhi SA, Levine OS, Hajjeh R, Mansoor OD, Cherian T. Vaccines to prevent pneumonia and improve child survival. Bull World Health Organ 2008;86(5):365-372.
52. Madhi SA, Schoub B, Klugman K P. Interaction between infuenza virus and Streptococcus pneumoniae in severe pneumonia. Expert Rev Respir Med 2008;2(5):663-672.
53. Madhi SA, Whitney CG, Nohynek H. Lessons learned from clinical trials evaluating pneumococcal conjugate vaccine efcacy against pneumonia and invasive disease. Vaccine 2008;26 Suppl 2:B9-B15.
54. Moore D P, Klugman K P, Madhi SA. Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confrmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J 2010;29(12):1099-1104.
55. Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodefciency virus-infected and uninfected children. Pediatr Infect Dis J 2005;24(5):410-416.
56. Madhi SA, Kuwanda L, Cutland C, Klugman K P. Te impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005;40(10):1511-1518.
57. Madhi SA, Adrian P, Kuwanda L, Cutland C, Albrich WC, Klugman KP. Long-term efect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae - and associated interactions with Staphylococcus aureus and Haemophilus infuenzae colonization - in HIV-infected and HIV-uninfected children. J Infect Dis 2007;196(11):1662-1666.
58. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efcacy of a 9-valent conjugate pneumococcal vaccine in human immunodefcient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007;25(13):2451-2457.
59. Madhi SA, Klugman KP, Kuwanda L, Cutland C, Kayhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years afer vaccination. J Infect Dis 2009;199(8):1168-1176.
60. Madhi SA, Adrian P, Cotton M F, et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010;202(3):355-361.
61. Madhi SA, Petersen K, Khoosal M, et al. Reduced efectiveness of Haemophilus infuenzae type b conjugate vaccine in children with a high prevalence of human immunodefciency virus type 1 infection. Pediatr Infect Dis J 2002;21(4):315-321.
62. Madhi SA, Kuwanda L, Saarinen L, et al. Immunogenicity and efectiveness of Haemophilus infuenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005;23(48-49):5517-5525.
63. Von Gottberg A, de Gouveia L, Madhi SA, et al. Impact of conjugate Haemophilus infuenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ 2006;84(10):811-818.
64. Mangtani P, Mulholland K, Madhi SA, Edmond K, O'Loughlin R, Hajjeh R. Haemophilus infuenzae type b disease in HIV-infected children: a review of the disease epidemiology and efectiveness of Hib conjugate vaccines. Vaccine 2010;28(7):1677-1683.
65. Madhi SA, Cunlife NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010;362(4):289-298.
66. Steele AD, Madhi SA, Louw CE, et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodefciency virus-positive infants in South Africa. Pediatr Infect Dis J 2011;30(2):125-130.
67. Madhi SA, Cutland C, Zhu Y, et al. Transmissibility, infectivity and immunogenicity of a live human parainfuenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine 2006;24(13):2432-2439.
68. Madhi SA, Mitha I, Cutland C, Groome M, Santos-Lima E. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J 2011;30(4):e68-74.
69. Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated infuenza vaccine in African adults infected with human immunodefcient virus: double blind, randomized clinical trial of efcacy, immunogenicity, and safety. Clin Infect Dis 2011;52(1):128-137.
70. Cutland CL, Madhi SA, Zell ER, et al. Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet 2009;374(9705):1909-1916.
71. Madhi SA, Nachman S, Violari A, et al. Lack of efcacy of primary isoniazid (INH) prophylaxis in increasing tuberculosis (TB) free survival in HIV-infected (HIV+) South African children. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA; 2008. http://www. abstractsonline.com/viewer/ViewAbstractPrintFriendly.asp?CKey={8FFD9D4C-306D-4E46-9494-3E5210078457}&MKey={26DFAE32-3D6D-446F-9AE5-B759FE42C683}&AKey={B156596F-4F2B-4B7B-9988-53EF0A523ACC}&SKey={96C1E1A3-3B51-4D15-9EB1-2FD66178CD03} (accessed 27 April 2011).
72. Brink A, Moolman J, da Silva MC, Botha M. National Antibiotic Surveillance Forum. Antimicrobial susceptibility profle of selected bacteraemic pathogens from private institutions in South Africa. S Afr Med J 2007;97(4):273-279.
73. Brink A, Feldman C, Richards G, Moolman J, Senekal M. Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer. S Afr Med J 2008;98(8):586-590 passim.
74. National Health Act (Act No. 6 of 2003) Regulations Regarding Communicable Diseases. Government Gazette No 30681, 25 January 2008:31-55.
75. Van den Broek PJ, Kluytmans JAJW, Ummels LC, Voss A, Vandenbroucke-Grauls CMJE. How many infection control staf do we need in hospitals? J Hosp Infect 2007; 65:108-111.
76. Mehtar S. Lowbury Lecture 2007: infection prevention and control strategies for tuberculosis in developing countries - lessons learnt from Africa. J Hosp Infect 2008;69(4):321-327.
77. Shishana O, Hall E, Maluleke KR, et al. The Impact of HIV/AIDS on the Health Sector. National Survey of health personnel, ambulatory and hospitalised patients and health facilities 2002. Human Sciences Research Council Press, 2003. www.hsrcpress.ac.za
78. Whitelaw A, Blake T, Rinquest C. Compliance with hand hygiene guidelines at Red Cross War Memorial Children's Hospital. UCT School of Child and Adolescent Health Research Day, Red Cross Children's Hospital, 2007.
79. Lubbe DE, Fagan JJ. South African survey on disinfection techniques for the fexible nasopharyngoscope. J Laryngol Otol 2003;117(10):811-814.
80. Mehtar S, Shisana O, Mosala T, Dunbar R. Infection control practices in public dental care services: fndings from one South African province. J Hosp Infect 2007;66(1):65-70. Epub 2007 Apr 11.
81. Marais E, Moodley A, Govender N, Kularatne R, Tomas J, Duse A. Clusters of Klebsiella pneumoniae infection in neonatal intensive care units in Gauteng. S Afr Med J 2006;96(9):813.
82. Moodley P, Coovadia YM, Sturm AW. Intravenous glucose preparation as the source of an outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infections in the neonatal unit of a regional hospital in KwaZulu-Natal. S Afr Med J 2005;95:861-864.
83. Van Nierop WH, Duse AG, Stewart RG, Bilgeri YR, Koornhof HJ. Molecular epidemiology of an outbreak of Enterobacter cloacae in the neonatal intensive care unit of a provincial hospital in Gauteng, South Africa. J Clin Microbiol 1998;36(10):3085-3087.
84. Marais E, de Jong G, Ferraz V, Maloba B, Duse AG. Interhospital transfer of pan-resistant Acinetobacter strains in Johannesburg, South Africa. Am J Infect Control 2004;32(5):278-281.
85. Jansen van Rensburg MJ, Eliya Madikane V, Whitelaw A, Chachage M, Hafejee S, Gay Elisha B. The dominant methicillin-resistant Staphylococcus aureus clone from hospitals in Cape Town has an unusual genotype: ST612. Clin Microbiol Infect 2011;May 17(5):785-792.
86. Gregersen N, van Nierop W, von Gottberg A, Duse A, Davies V, Cooper P. Klebsiella pneumoniae with extended spectrum beta-lactamase activity associated with a necrotizing enterocolitis outbreak. Pediatr Infect Dis J 1999;18(11):963-967.
87. Rosenthal VD. Health-care-associated infections in developing countries. Lancet 2011;37:186-188.
88. US Agency for Healthcare Research and Quality (AHRQ). Hospital Survey on Patient Safety Culture. March 2011. http://www.ahrq.gov/qual/patientsafetyculture/hospsurvindex.htm (accessed 15 July 2011).
89. Gawande A. Checklist Manifesto. London: Profle Books, 2010.
90. Haynes AB, Weiser TG, Berry WR, et al. A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med 2009;360:491-499.
91. De Vries EN, Prins HA, Crolla RM, et al. Effect of a comprehensive surgical safety system on patient outcomes. N Engl J Med 2010;363:1928-1937.
92. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355:2725-2732.
93. McGlynn E, Asch SM, Adam J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003; 348:2635-2645.